Although not coming from head-to-head studies, supporting evidence for similar properties across these radioligands is provided by a cross-sectional study pooling flortaucipir, RO948 and florquinitau data.416 This study demonstrates that tau-PET binding across several regions, e.g. entorhinal cortex or a temporal composite ROI, provides similar accuracy in differentiating Alzheimer’s disease versus non-Alzheimer’s disease or cognitively normal participants across tracers.416. Here, MAPT is linked to Alzheimer disease.